Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Preferred Shares (2023 - 2025)

SAB Biotherapeutics (SABS) has disclosed Preferred Shares for 3 consecutive years, with $64.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Preferred Shares rose 1180.0% year-over-year to $64.0, compared with a TTM value of $64.0 through Dec 2025, up 1180.0%, and an annual FY2025 reading of $64.0, up 1180.0% over the prior year.
  • Preferred Shares was $64.0 for Q4 2025 at SAB Biotherapeutics, roughly flat from $64.0 in the prior quarter.
  • Across five years, Preferred Shares topped out at $64.0 in Q3 2025 and bottomed at $5.0 in Q4 2023.
  • Average Preferred Shares over 3 years is $18.11, with a median of $5.0 recorded in 2023.
  • The sharpest move saw Preferred Shares changed 0.0% in 2024, then soared 1180.0% in 2025.
  • Year by year, Preferred Shares stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then skyrocketed by 1180.0% to $64.0 in 2025.
  • Business Quant data shows Preferred Shares for SABS at $64.0 in Q4 2025, $64.0 in Q3 2025, and $5.0 in Q2 2025.